BSE filing, NSE: PILITA. Summary written from the filing by ALFA Finder's alert engine.
Pil Italica Lifestyle Ltd: key numbers
- Share price
- ₹6.96
- Market cap
- ₹163.6 Cr
- Revenue (annual)
- ₹108.3 Cr
- Net profit (annual)
- ₹4.49 Cr
- P/E (TTM)
- 71.4×Sector 50.9×
- Promoter holding
- 50.09%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Pil Italica Lifestyle Ltd
All →Pil Italica Lifestyle Results Update
Pil Italica Lifestyle released its business update for Q2 and H1 FY27. The report includes key operational highlights and quarterly financial performance metrics.
- total consolidated production capacity
- 8450.0 MTPA
Pil Italica Lifestyle Q2 FY27 Results: Net Profit ₹0.3 Cr, Down 72.7% YoY
Pil Italica Lifestyle Ltd reported revenue from operations of ₹28.2 Cr (+2.2% YoY) and net profit of ₹0.3 Cr (-72.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹0.3 Cr · -72.7% YoY
Pil Italica Lifestyle Board Meeting Date
Pil Italica Lifestyle scheduled its Board of Directors meeting on 21 October 2026 to consider unaudited financial results for Q2 and H1 FY27. No financial figures or decisions are included in this advance intimation.
Pil Italica Lifestyle Other Announcement
The company submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the period ended September 30, 2026.
Pil Italica Lifestyle Credit Rating
CARE Ratings Limited has reaffirmed the credit rating of Pil Italica Lifestyle Limited at BBB- with a Stable outlook.
Pil Italica Lifestyle Credit Rating
Care Ratings Limited reaffirmed the 'CARE BBB-; Stable' rating on PIL Italica Lifestyle Limited's bank facilities totaling ₹15 Crore.
- Value
- ₹15.00 Cr
Other business update announcements
All →Skyways Air Services Business Update
Skyways Air Services renewed its Global Annual Agreement with Qatar Airways for one year. The agreement's size is not quantifiable, so no value is assigned.
- From
- Qatar Airways Group Q.C.S.C.
- Execution
- 1 year from effective date 1 January 2026
Zydus Lifesciences Business Update
Zydus Lifesciences' subsidiary presented Phase 2b trial data for investigational saroglitazar in MASH at AASLD 2026. The drug showed higher steatohepatitis resolution than placebo, but its safety and effectiveness for this use are not yet established.
Rajshree Sugars & Chemicals Business Update
Rajshree Sugars reported October 2026 operational data for its three sugar units. Sugar sales were 17,849 MT, with no cane crushed during the month.
Fino Payments Bank Business Update
Fino Payments Bank's October 2026 update showed deposits crossing Rs 3,000 Crore for the first time. Loan referral disbursals rose 316% year-on-year to Rs 301 Crore.
Ugar Sugar Works Business Update
Ugar Sugar Works has informed the exchanges that crushing for the 2026-27 season started at its Ugar Unit on 06 Nov 2026. Crushing will ramp up to full capacity over time.
Aarti Drugs Business Update
Aarti Drugs disclosed that the US FDA inspected its subsidiary Pinnacle Life Science's Baddi plant on 2-6 November 2026 and issued three Form 483 observations. The company states there is no financial or operational impact.